凝血因子V妊娠结局亚甲基四氢叶酸还原酶FVL突变G20210A蛋白C抵抗母儿血栓栓塞血栓形成倾向目的:评价无血栓栓塞病史的凝血因子V Leiden(FVL)突变携带者妊娠相关血栓事件的发生率,以及母体和胎儿携带FVL突变或其他血栓形成倾向危险因素对预后的影响.方法:2000年4月至2001年8月,在13个医疗中心收集单胎,无血栓栓塞病史,孕...
In a small substudy (N = 81) of the NSABP-1 trial, there appeared to be no benefit to screening women for Factor V Leiden and Prothrombin mutations G20210A as a means to identify those who may not be appropriate candidates for tamoxifen therapy. In the NSABP P-1 trial, there was an...
In a small substudy (N = 81) of the NSABP-1 trial, there appeared to be no benefit to screening women for Factor V Leiden and Prothrombin mutations G20210A as a means to identify those who may not be appropriate candidates for tamoxifen therapy. Data from the NSABP P-1 trial show ...
The correlation for LVs with prior information is significantly lower for all but one technical factor (PF_ALIGNED_BASES). Boxplots display the 25th, 50th and 75th percentile, with whiskers extending to 1.5x the interquartile range or the range of the data whichever is smallest. Supplementary ...
Factor Type(s) Trait Sample Characteristic(s) Scleractinia • marine coral reef biome Machine-accessible metadata file describing the reported data (ISA-Tab format) Similar content being viewed by others Ancient Reef Traits, a database of trait information for reef-building organisms over the Phane...
Rheumatoid factor PPV: Positive predictive value NPV: Negative predictive value pSS: Primary Sjögren’s syndrome References van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann N Y Acad Sci. 2008;1143:268–85. Ar...
Sommige onderzoeken lijken erop te wijzen dat de tijd die een persoon spendeert aan een activiteit ook een bepalende factor kan zijn. Enkele richtlijnen die kunnen helpen om comfortabeler te werken en te spelen en die de kans op het oplopen van ...
Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists. January 01, 2005 [MEDLINE Abstract] Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic ...
Consider the potential for an increased risk of thromboembolism when administering PROMACTA to patients with known risk factors for thromboembolism (e.g., Factor V Leiden, ATIII deficiency, antiphospholipid syndrome, chronic liver disease). To minimize the risk for thrombotic/thromboembolic complications,...
Consider the potential increased thrombotic risk when administering MULPLETA to patients with known risk factors for thromboembolism, including genetic pro-thrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency, or Protein C or S deficiency). In patients with ongoing or prior...